基因克隆服务的全球市场：市场规模和份额分析（按服务、按应用、按基因类型、按最终用户）、行业需求预测（截至 2030 年）

市场概况

2023年全球基因克隆服务市场规模预估为31.541亿美元，2024年至2030年复合年增长率为18.1%，预计到2030年将达到100.196亿美元。

慢性病的增加、对精准药物的需求增加以及遗传疾病的显着发病率预计将有助于该行业的发展。 此外，政府支出的增加、生物技术领域的研发以及遗传学技术的进步预计将导致製药领域的研究大幅成长，从而在未来几年增加行业收入。

关键见解

2023年，基因合成品类将占产业份额45□□%。 它的流行得益于其在众多垂直领域的广泛应用以及全球研究活动的成长。

2023年，基因治疗将占产业份额35%。 它的成长潜力在于它能够治疗以前无法治癒的疾病。

由于生物技术和製药行业的积极研发，截至 2023 年，北美地区占据该行业最大份额，约为 55%。

本报告分析了全球基因克隆服务市场，包括市场的基本结构和最新情况、主要促进和限制因素以及全球、按地区、主要国家（货币单位）的市场规模前景。按服务、应用、基因类型和最终用户划分的详细趋势、市场竞争的现状以及主要公司的概况。

目录

第1章研究范围

第2章研究方法

第 3 章执行摘要

第 4 章市场指标

第5章产业展望

• 市场动态
  • 趋势
  • 促进因素
  • 抑制因素/挑战
  • 促进/抑制因子影响分析
• 新型冠状病毒感染 (COVID-19) 的影响
• 波特五力分析

第6章世界市场

• 摘要
• 市场收入：依服务划分（2017-2030 年）
• 市场收入：依应用分类（2017-2030 年）
• 市场收入：依基因类型划分（2017-2030 年）
• 市场收入：以最终用户划分（2017-2030 年）
• 市场收入：按地区划分（2017-2030 年）

第7章北美市场

• 摘要
• 市场收入：依服务划分（2017-2030 年）
• 市场收入：依应用分类（2017-2030 年）
• 市场收入：依基因类型划分（2017-2030 年）
• 市场收入：以最终用户划分（2017-2030 年）
• 市场收入：依国家/地区划分（2017-2030 年）

第8章欧洲市场

第9章亚太市场

第10章拉丁美洲市场

第11章中东及非洲市场

第12章美国市场

• 摘要
• 市场收入：依服务划分（2017-2030 年）
• 市场收入：依应用分类（2017-2030 年）
• 市场收入：依基因类型划分（2017-2030 年）
• 市场收入：以最终用户划分（2017-2030 年）

第13章加拿大市场

第14章德国市场

第15章法国市场

第16章英国市场

第17章义大利市场

第18章西班牙市场

第19章日本市场

第20章中国市场

第21章印度市场

第22章澳洲市场

第23章韩国市场

第24章巴西市场

第25章墨西哥市场

第26章沙乌地阿拉伯市场

第27章南非市场

第 28 章阿联酋 (UAE) 市场

第29章竞争态势

• 市场参与者及其提供的产品/服务的列表
• 主要公司的竞争基准
• 各大公司的产品基准
• 近期策略发展状况

第30章公司简介

• Thermo Fisher Scientific Inc.
• Genscript Biotech Corporation
• Eurofins Scientific SE
• Charles River Laboratories International Inc.
• Takara Bio Inc.
• Creative Biogene
• Synbio Technologies
• Aragen Life Sciences Ltd.
• Sino Biological Inc.
• Curia Global Inc.

第31章 附录

Market Overview

The market value of global gene cloning services is estimated to be USD 3,154.1 million in 2023 and is projected to reach USD 10,019.6 million by 2030, with a Compound Annual Growth Rate (CAGR) of 18.1% during the period from 2024 to 2030.

The rising occurrence of chronic illnesses, the growing need for accurate drugs, and the substantial occurrence of inherited conditions are projected to contribute to the development of the industry. Moreover, the substantial surge in research in the medicinal field because of the rise in spending by governments, the development of the biotechnological sector, and technical improvements in genetics are projected to propel the industry revenue in the coming years.

Nowadays we see a growing trend of a sedentary way of life, which goes with alcohol consumption, increased smoking, terminal fast food, and exercise too rare. The adoption of this unhealthy diet is causing the state of health of people to be even more unhealthy and also the development of many long-term diseases.

Diseases make things worse and serious diseases will be the things that can even end the life of a person. This therefore led to an increase in the need for such methods of treatments that are either more efficient or more effective in curing the disease.

Key Insights

In 2023, the gene synthesis category grips the dominating industry share of 45%.

Its acceptance stems from its extensive application in numerous verticals and the growing research activities globally.

Researchers are progressively using gene synthesis along with techs such as CRISPR genome editing and synthetic biology for enhanced solutions in life sciences.

Gene synthesis can be used in the fields of neurosciences, therapeutic antibody structure development, plant biology, cancer biology, genetics, and biochemistry.

Initially, it is considered a tool pushed to the front for economical tasks of the traditional cloning and molecular biology method that sometimes need time and are expensive.

In 2023, gene therapy grips a leading industry share of 35%.

Its potential lies in its capability to cure previously irredeemable ailments or diseases.

More than 50,000 inherited illnesses caused by gene mutations have been recognized, making gene treatment a promising method.

Understanding protein pathways and gene expression allows for the testing and effectiveness of more therapies.

In 2023, the North American region holds the largest industry share of approximately 55% because of substantial R&D in the biotechnology and pharmaceutical industries.

Reasons contributing to this comprise the high occurrence of chronic illnesses, a strong healthcare system, and acceptance of enhanced technologies.

Top biotechnology businesses and genomic research projects with significant investments are propelling industry development.

Positive perceptions of health and genetic testing to individuals may stimulate research of genomics in medicine to evaluate therapeutic purposes.

Due to the well-established healthcare, general public knowledge, and individual capacity of a modern person to cover the expenses related to treatment, and along with the implementation of gene therapies for cancer, Canada provides the largest market share in North America.

Enhanced healthcare coverage as well as steady improvement of pharmaceutical and biotech industries is going to result in a substantial portion in the forecast. Additionally, rising chronic diseases, and growing gene cloning in diagnostic and drug development, will support Europe in ranking within the top five markets.

Table of Contents

Chapter 1. Research Scope

• 1.1. Research Objectives
• 1.2. Market Definition
• 1.3. Analysis Period
• 1.4. Market Size Breakdown by Segments
  • 1.4.1. Market size breakdown, by service
  • 1.4.2. Market size breakdown, by application
  • 1.4.3. Market size breakdown, by gene type
  • 1.4.4. Market size breakdown, by end user
  • 1.4.5. Market size breakdown, by region
  • 1.4.6. Market size breakdown, by country
• 1.5. Market Data Reporting Unit
  • 1.5.1. Value
• 1.6. Key Stakeholders

Chapter 2. Research Methodology

• 2.1. Secondary Research
  • 2.1.1. Paid
  • 2.1.2. Unpaid
  • 2.1.3. P&S Intelligence database
• 2.2. Primary Research
• 2.3. Market Size Estimation
• 2.4. Data Triangulation
• 2.5. Currency Conversion Rates
• 2.6. Assumptions for the Study
• 2.7. Notes and Caveats

Chapter 3. Executive Summary

Chapter 4. Market Indicators

Chapter 5. Industry Outlook

• 5.1. Market Dynamics
  • 5.1.1. Trends
  • 5.1.2. Drivers
  • 5.1.3. Restraints/challenges
  • 5.1.4. Impact analysis of drivers/restraints
• 5.2. Impact of COVID-19
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Bargaining power of buyers
  • 5.3.2. Bargaining power of suppliers
  • 5.3.3. Threat of new entrants
  • 5.3.4. Intensity of rivalry
  • 5.3.5. Threat of substitutes

Chapter 6. Global Market

• 6.1. Overview
• 6.2. Market Revenue, by Service (2017-2030)
• 6.3. Market Revenue, by Application (2017-2030)
• 6.4. Market Revenue, by Gene Type (2017-2030)
• 6.5. Market Revenue, by End User (2017-2030)
• 6.6. Market Revenue, by Region (2017-2030)

Chapter 7. North America Market

• 7.1. Overview
• 7.2. Market Revenue, by Service (2017-2030)
• 7.3. Market Revenue, by Application (2017-2030)
• 7.4. Market Revenue, by Gene Type (2017-2030)
• 7.5. Market Revenue, by End User (2017-2030)
• 7.6. Market Revenue, by Country (2017-2030)

Chapter 8. Europe Market

• 8.1. Overview
• 8.2. Market Revenue, by Service (2017-2030)
• 8.3. Market Revenue, by Application (2017-2030)
• 8.4. Market Revenue, by Gene Type (2017-2030)
• 8.5. Market Revenue, by End User (2017-2030)
• 8.6. Market Revenue, by Country (2017-2030)

Chapter 9. APAC Market

• 9.1. Overview
• 9.2. Market Revenue, by Service (2017-2030)
• 9.3. Market Revenue, by Application (2017-2030)
• 9.4. Market Revenue, by Gene Type (2017-2030)
• 9.5. Market Revenue, by End User (2017-2030)
• 9.6. Market Revenue, by Country (2017-2030)

Chapter 10. LATAM Market

• 10.1. Overview
• 10.2. Market Revenue, by Service (2017-2030)
• 10.3. Market Revenue, by Application (2017-2030)
• 10.4. Market Revenue, by Gene Type (2017-2030)
• 10.5. Market Revenue, by End User (2017-2030)
• 10.6. Market Revenue, by Country (2017-2030)

Chapter 11. MEA Market

• 11.1. Overview
• 11.2. Market Revenue, by Service (2017-2030)
• 11.3. Market Revenue, by Application (2017-2030)
• 11.4. Market Revenue, by Gene Type (2017-2030)
• 11.5. Market Revenue, by End User (2017-2030)
• 11.6. Market Revenue, by Country (2017-2030)

Chapter 12. U.S. Market

• 12.1. Overview
• 12.2. Market Revenue, by Service (2017-2030)
• 12.3. Market Revenue, by Application (2017-2030)
• 12.4. Market Revenue, by Gene Type (2017-2030)
• 12.5. Market Revenue, by End User (2017-2030)

Chapter 13. Canada Market

• 13.1. Overview
• 13.2. Market Revenue, by Service (2017-2030)
• 13.3. Market Revenue, by Application (2017-2030)
• 13.4. Market Revenue, by Gene Type (2017-2030)
• 13.5. Market Revenue, by End User (2017-2030)

Chapter 14. Germany Market

• 14.1. Overview
• 14.2. Market Revenue, by Service (2017-2030)
• 14.3. Market Revenue, by Application (2017-2030)
• 14.4. Market Revenue, by Gene Type (2017-2030)
• 14.5. Market Revenue, by End User (2017-2030)

Chapter 15. France Market

• 15.1. Overview
• 15.2. Market Revenue, by Service (2017-2030)
• 15.3. Market Revenue, by Application (2017-2030)
• 15.4. Market Revenue, by Gene Type (2017-2030)
• 15.5. Market Revenue, by End User (2017-2030)

Chapter 16. U.K. Market

• 16.1. Overview
• 16.2. Market Revenue, by Service (2017-2030)
• 16.3. Market Revenue, by Application (2017-2030)
• 16.4. Market Revenue, by Gene Type (2017-2030)
• 16.5. Market Revenue, by End User (2017-2030)

Chapter 17. Italy Market

• 17.1. Overview
• 17.2. Market Revenue, by Service (2017-2030)
• 17.3. Market Revenue, by Application (2017-2030)
• 17.4. Market Revenue, by Gene Type (2017-2030)
• 17.5. Market Revenue, by End User (2017-2030)

Chapter 18. Spain Market

• 18.1. Overview
• 18.2. Market Revenue, by Service (2017-2030)
• 18.3. Market Revenue, by Application (2017-2030)
• 18.4. Market Revenue, by Gene Type (2017-2030)
• 18.5. Market Revenue, by End User (2017-2030)

Chapter 19. Japan Market

• 19.1. Overview
• 19.2. Market Revenue, by Service (2017-2030)
• 19.3. Market Revenue, by Application (2017-2030)
• 19.4. Market Revenue, by Gene Type (2017-2030)
• 19.5. Market Revenue, by End User (2017-2030)

Chapter 20. China Market

• 20.1. Overview
• 20.2. Market Revenue, by Service (2017-2030)
• 20.3. Market Revenue, by Application (2017-2030)
• 20.4. Market Revenue, by Gene Type (2017-2030)
• 20.5. Market Revenue, by End User (2017-2030)

Chapter 21. India Market

• 21.1. Overview
• 21.2. Market Revenue, by Service (2017-2030)
• 21.3. Market Revenue, by Application (2017-2030)
• 21.4. Market Revenue, by Gene Type (2017-2030)
• 21.5. Market Revenue, by End User (2017-2030)

Chapter 22. Australia Market

• 22.1. Overview
• 22.2. Market Revenue, by Service (2017-2030)
• 22.3. Market Revenue, by Application (2017-2030)
• 22.4. Market Revenue, by Gene Type (2017-2030)
• 22.5. Market Revenue, by End User (2017-2030)

Chapter 23. South Korea Market

• 23.1. Overview
• 23.2. Market Revenue, by Service (2017-2030)
• 23.3. Market Revenue, by Application (2017-2030)
• 23.4. Market Revenue, by Gene Type (2017-2030)
• 23.5. Market Revenue, by End User (2017-2030)

Chapter 24. Brazil Market

• 24.1. Overview
• 24.2. Market Revenue, by Service (2017-2030)
• 24.3. Market Revenue, by Application (2017-2030)
• 24.4. Market Revenue, by Gene Type (2017-2030)
• 24.5. Market Revenue, by End User (2017-2030)

Chapter 25. Mexico Market

• 25.1. Overview
• 25.2. Market Revenue, by Service (2017-2030)
• 25.3. Market Revenue, by Application (2017-2030)
• 25.4. Market Revenue, by Gene Type (2017-2030)
• 25.5. Market Revenue, by End User (2017-2030)

Chapter 26. Saudi Arabia Market

• 26.1. Overview
• 26.2. Market Revenue, by Service (2017-2030)
• 26.3. Market Revenue, by Application (2017-2030)
• 26.4. Market Revenue, by Gene Type (2017-2030)
• 26.5. Market Revenue, by End User (2017-2030)

Chapter 27. South Africa Market

• 27.1. Overview
• 27.2. Market Revenue, by Service (2017-2030)
• 27.3. Market Revenue, by Application (2017-2030)
• 27.4. Market Revenue, by Gene Type (2017-2030)
• 27.5. Market Revenue, by End User (2017-2030)

Chapter 28. U.A.E. Market

• 28.1. Overview
• 28.2. Market Revenue, by Service (2017-2030)
• 28.3. Market Revenue, by Application (2017-2030)
• 28.4. Market Revenue, by Gene Type (2017-2030)
• 28.5. Market Revenue, by End User (2017-2030)

Chapter 29. Competitive Landscape

• 29.1. List of Market Players and their Offerings
• 29.2. Competitive Benchmarking of Key Players
• 29.3. Product Benchmarking of Key Players
• 29.4. Recent Strategic Developments

Chapter 30. Company Profiles

• 30.1. Thermo Fisher Scientific Inc.
  • 30.1.1. Business overview
  • 30.1.2. Product and service offerings
  • 30.1.3. Key financial summary
• 30.2. Genscript Biotech Corporation
  • 30.2.1. Business overview
  • 30.2.2. Product and service offerings
  • 30.2.3. Key financial summary
• 30.3. Eurofins Scientific SE
  • 30.3.1. Business overview
  • 30.3.2. Product and service offerings
  • 30.3.3. Key financial summary
• 30.4. Charles River Laboratories International Inc.
  • 30.4.1. Business overview
  • 30.4.2. Product and service offerings
  • 30.4.3. Key financial summary
• 30.5. Takara Bio Inc.
  • 30.5.1. Business overview
  • 30.5.2. Product and service offerings
  • 30.5.3. Key financial summary
• 30.6. Creative Biogene
  • 30.6.1. Business overview
  • 30.6.2. Product and service offerings
  • 30.6.3. Key financial summary
• 30.7. Synbio Technologies
  • 30.7.1. Business overview
  • 30.7.2. Product and service offerings
  • 30.7.3. Key financial summary
• 30.8. Aragen Life Sciences Ltd.
  • 30.8.1. Business overview
  • 30.8.2. Product and service offerings
  • 30.8.3. Key financial summary
• 30.9. Sino Biological Inc.
  • 30.9.1. Business overview
  • 30.9.2. Product and service offerings
  • 30.9.3. Key financial summary
• 30.10. Curia Global Inc.
  • 30.10.1. Business overview
  • 30.10.2. Product and service offerings
  • 30.10.3. Key financial summary

Chapter 31. Appendix

• 31.1. Abbreviations
• 31.2. Sources and References
• 31.3. Related Reports